Nothing said here yet.
to join the conversation.
| Buell JenniferChief Executive Officer | Sell | 6,938 | $73.3K | Mon, Oct 12 |
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand access to cell-based medicines NEW YORK, Sept.
Net loss narrowed to $3.1 million as Phase 2 trial for agenT-797 advances in Ukraine.
Moby summary of MiNK Therapeutics, Inc.'s Q2 2026 earnings call
MiNK Therapeutics reports encouraging initial data from its ARDS study, narrows net loss, and expands international access programs despite a tight cash position.
MiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026.
First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor supportClinical recovery and biologic readouts moved in the…
First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor supportAnalysis of blood and lung fluid showed signals of infection control and…
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.
MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.